Speaking at PMWC 2026

Today at PMWC 2026, our Founder and CEO Lalin Theverapperuma, PhD will presented Limited Sample Model (LSM) — a new AI architecture designed for regulated, data-scarce environments where accuracy, governance, and auditability define performance.

Large foundation models are powerful, but in pharmaceutical and clinical workflows, scale alone does not solve the hardest problems. Validation, traceability, and defensible decisions matter.

Session:
Limited Sample Models for Faster Lead Discovery, High Accuracy, and Regulatory Grade AI
2:30 PM
Track 2: AI in Drug Discovery & Computational Biology

If you’re attending PMWC 2026, see the session to learn how purpose-built AI architectures enable governed, regulatory-grade decisions across scientific workflows.

Stop by Booth B605 to see Limited Sample Model in action and explore how governed, sparse-data AI fits into real laboratory infrastructure.

#PMWC2026 #PrecisionMedicine #DrugDiscovery #Biopharma #RegulatedAI #AIInfrastructure #ExpertIntelligence